Acivicin

Acivicin
Names
IUPAC name
(2S)-Amino[(5S)-3-chloro-4,5-dihydro-1,2-oxazol-5-yl]ethanoic acid
Other names
Antibiotic AT 125
Identifiers
CAS Number
  • 42228-92-2 ☒N
3D model (JSmol)
  • Interactive image
ChEBI
  • CHEBI:74545 ☒N
ChEMBL
  • ChEMBL1231101 ☒N
ChemSpider
  • 259938 checkY
PubChem CID
  • 294641
UNII
  • O0X60K76I6 checkY
CompTox Dashboard (EPA)
  • DTXSID0046010 Edit this at Wikidata
InChI
  • InChI=1S/C5H7ClN2O3/c6-3-1-2(11-8-3)4(7)5(9)10/h2,4H,1,7H2,(H,9,10)/t2-,4-/m0/s1 checkY
    Key: QAWIHIJWNYOLBE-OKKQSCSOSA-N checkY
  • InChI=1S/C5H7ClN2O3/c6-3-1-2(11-8-3)4(7)5(9)10/h2,4H,1,7H2,(H,9,10)/t2-,4-/m0/s1
  • Cl\C1=N\O[C@H]([C@@H](C(=O)O)N)C1
Properties
Chemical formula
C5H7ClN2O3
Molar mass 178.574
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references
Chemical compound

Acivicin is an analog of glutamine. It is an inhibitor of gamma-glutamyl transferase.

It is a fermentation product of Streptomyces sviceus.[1] It interferes with glutamate metabolism and inhibits glutamate dependent synthesis of enzymes, and is thereby potentially helpful in treatment of solid tumors.[2]

After its discovery in 1972, acivicin was studied as an anti-cancer agent, but trials were unsuccessful due to toxicity.[3]

Research

An in vitro study showed that Acivicin at a concentration of 5 μM Acivicin inhibited by 78% the growth of human pancreatic carcinoma cells (MIA PaCa-2) after 72 hours in continuous culture. It was also found that acivicin at a concentration of 450 μM irreversibly inactivated MIA PaCa-2 γ-glutamyl transpeptidase (10 nmol/min/106 cells) with an inactivation half-life of 80 minutes.[1]

Phase I studies

Phase I dose escalating studies conducted in 23 cancer patients administered acivicin with a concomitant 96-h i.v. infusion of a mixture of 16 amino acids showed reversible, dose-limiting CNS toxicity, characterized by lethargy, confusion and decreased mental status.

References

  1. ^ a b Allen, L.; Meck, R.; Yunis, A. (1980). "The Inhibition of γ-Glutamyl Transpeptidase from Human Pancreatic Carcinoma Cells by (αS,5S)-α-Amino-3-chloro-4,5-dihydro-5-isoxazoleacetic Acid (AT-125; NSC-163501)". Research Communications in Chemical Pathology and Pharmacology. 27 (1): 175–182. PMID 6102405.
  2. ^ Hidalgo, M.; Rodriguez, G.; Kuhn, J. G.; Brown, T.; Weiss, G.; MacGovren, J. P.; von Hoff, D. D.; Rowinsky, E. K. (1998). "A Phase I and Pharmacological Study of the Glutamine Antagonist Acivicin with the Amino Acid Solution Aminosyn in Patients with Advanced Solid Malignancies". Clinical Cancer Research. 4 (11): 2763–2770. PMID 9829740.
  3. ^ Kreuzer, Johannes; Bach, Nina C.; Forler, Daniel; Sieber, Stephan A. (2015). "Target discovery of acivicin in cancer cells elucidates its mechanism of growth inhibition". Chemical Science. 6 (1): 237–245. doi:10.1039/C4SC02339K. PMC 4285139. PMID 25580214.

External links

  • Obrador, E.; Carretero, J.; Ortega, A.; Medina, I.; Rodilla, V.; Pellicer, J. A.; Estrela, J. M. (2002). "γ-Glutamyl Transpeptidase Overexpression Increases Metastatic Growth of B16 Melanoma Cells in the Mouse Liver". Hepatology. 35 (1): 74–81. doi:10.1053/jhep.2002.30277. PMID 11786961.
  • Schmees, C.; Prinz, C.; Treptau, T.; Rad, R.; Hengst, L.; Voland, P.; Bauer, S.; Brenner, L.; Schmid, R. M.; Gerhard, M. (2007). "Inhibition of T-Cell Proliferation by Helicobacter pylori γ-Glutamyl Transpeptidase". Gastroenterology. 132 (5): 1820–1833. doi:10.1053/j.gastro.2007.02.031. PMID 17484877.
  • v
  • t
  • e
Receptor
(ligands)
BLTTooltip Leukotriene B4 receptor
BLT1Tooltip Leukotriene B4 receptor 1
  • Agonists: 12-HETE
  • 20-Hydroxy-LTB4
  • Leukotriene B4
  • LY-255283
  • Antagonists: 20-Carboxy-LTB4
  • Amelubant
  • CGS-23131 (LY-223982)
  • CGS-25019C
  • CP-105696
  • CP-195543
  • Etalocib
  • LY-293111
  • Moxilubant
  • ONO-4057
  • RG-14893
  • RP-69698
  • SB-209247
  • SC-53228
  • Ticolubant
  • U-75302
  • ZK-158252
BLT2Tooltip Leukotriene B4 receptor 2
  • Antagonists: CP-195543
  • LY-255283
  • ZK-158252
CysLTTooltip Cysteinyl leukotriene receptor
CysLT1Tooltip Cysteinyl leukotriene receptor 1
  • Agonists: Leukotriene C4
  • Leukotriene D4
  • Leukotriene E4
  • Antagonists: Ablukast
  • BAYu9773
  • BAYu9916
  • BAYx7195
  • Cinalukast
  • FPL-55712
  • ICI-198615
  • Iralukast
  • LY-170680
  • Masilukast
  • MK-571
  • Montelukast
  • ONO-1078
  • Pobilukast
  • Pranlukast
  • Ritolukast
  • SKF-104353
  • SR-2640
  • Sulukast
  • Tipelukast
  • Tomelukast
  • Verlukast
  • Zafirlukast
  • ZD-3523
CysLT2Tooltip Cysteinyl leukotriene receptor 2
  • Agonists: Leukotriene C4
  • Leukotriene D4
  • Leukotriene E4
  • Antagonists: BAYu9773
  • BAYu9916
CysLTETooltip Cysteinyl leukotriene receptor E
  • Agonists: Leukotriene E4
Enzyme
(inhibitors)
5-LOXTooltip Arachidonate 5-lipoxygenase
  • FLAPTooltip Arachidonate 5-lipoxygenase-activating protein inhibitors: AM-103
  • AM-679
  • BAYx1005
  • MK-591
  • MK-886
12-LOXTooltip Arachidonate 12-lipoxygenase
15-LOXTooltip Arachidonate 15-lipoxygenase
LTA4HTooltip Leukotriene A4 hydrolase
LTB4HTooltip Leukotriene B4 ω-hydroxylase
  • 17-Octadecynoic acid
LTC4STooltip Leukotriene C4 synthase
LTC4HTooltip Leukotriene C4 hydrolase
  • Acivicin
  • Serine-borate complex
LTD4Tooltip Leukotriene D4 hydrolase
Others
See also
Receptor/signaling modulators
Prostanoid signaling modulators


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e